Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma

Malignant glioma, the most common primary brain tumor, is generally incurable. Although phosphatidylinositol-3-kinase (PI3K) signaling features prominently in glioma, inhibitors generally block proliferation rather than induce apoptosis. Starting with an inhibitor of both lipid and protein kinases that induced prominent apoptosis and that failed early clinical development because of its broad target profile and overall toxicity, we identified protein kinase targets, the blockade of which showed selective synthetic lethality when combined with PI3K inhibitors. Prioritizing protein kinase targets for which there are clinical inhibitors, we demonstrate that cyclin-dependent kinase (CDK)1/2 inhibitors, siRNAs against CDK1/2, and the clinical CDK1/2 inhibitor roscovitine all cooperated with the PI3K inhibitor PIK-90, blocking the antiapoptotic protein Survivin and driving cell death. In addition, overexpression of CDKs partially blocked some of the apoptosis caused by PIK-75. Roscovitine and PIK-90, in combination, were well tolerated in vivo and acted in a synthetic-lethal manner to induce apoptosis in human glioblastoma xenografts. We also tested clinical Akt and CDK inhibitors, demonstrating induction of apoptosis in vitro and providing a preclinical rationale to test this combination therapy in patients.

[1]  L. Carbone.  Pain management standards in the eighth edition of the Guide for the Care and Use of Laboratory Animals. , 2012, Journal of the American Association for Laboratory Animal Science : JAALAS.

[2]  C. James,et al.  Akt and Autophagy Cooperate to Promote Survival of Drug-Resistant Glioma , 2010, Science Signaling.

[3]  E. Lees,et al.  Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor , 2010, Molecular Cancer Therapeutics.

[4]  P. Majumder,et al.  MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo , 2010, Molecular Cancer Therapeutics.

[5]  I. Tannock,et al.  Concurrent and Sequential Administration of Chemotherapy and the Mammalian Target of Rapamycin Inhibitor Temsirolimus in Human Cancer Cells and Xenografts , 2009, Clinical Cancer Research.

[6]  P. Yaswen,et al.  A Versatile Viral System for Expression and Depletion of Proteins in Mammalian Cells , 2009, PloS one.

[7]  A. Giordano,et al.  Cell cycle kinases as therapeutic targets for cancer , 2009, Nature Reviews Drug Discovery.

[8]  A. Hui,et al.  Therapeutic Efficacy of Seliciclib in Combination with Ionizing Radiation for Human Nasopharyngeal Carcinoma , 2009, Clinical Cancer Research.

[9]  M. Barbacid,et al.  Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.

[10]  M. Salto‐Tellez,et al.  Pharmacodynamic Effects of Seliciclib, an Orally Administered Cell Cycle Modulator, in Undifferentiated Nasopharyngeal Cancer , 2009, Clinical Cancer Research.

[11]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[12]  Daniela Gabriel,et al.  Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity , 2008, Molecular Cancer Therapeutics.

[13]  K. Shokat,et al.  A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. , 2007, Cancer research.

[14]  M. Waterfield,et al.  Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2 -a]pyridines as novel PI3 kinase p110α inhibitors , 2007 .

[15]  P. Workman,et al.  A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days , 2006, British Journal of Cancer.

[16]  P. Mayinger.  Faculty Opinions recommendation of A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. , 2006 .

[17]  Robbie Loewith,et al.  A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling , 2006, Cell.

[18]  William A Weiss,et al.  A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. , 2006, Cancer cell.

[19]  C. James,et al.  Use of an Orthotopic Xenograft Model for Assessing the Effect of Epidermal Growth Factor Receptor Amplification on Glioblastoma Radiation Response , 2006, Clinical Cancer Research.

[20]  W. Weiss,et al.  RNA interference against a glioma-derived allele of EGFR induces blockade at G2M , 2005, Oncogene.

[21]  Richard D. Byrne,et al.  Bisperoxovanadium compounds are potent PTEN inhibitors , 2004, FEBS letters.

[22]  Eun Hee Kim,et al.  Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP , 2004, Oncogene.

[23]  Chao Zhang,et al.  Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach. , 2003, Cancer research.

[24]  S. Korsmeyer,et al.  Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death , 2001, Science.

[25]  S. van den Heuvel,et al.  S and G2 Phase Roles for Cdk2 Revealed by Inducible Expression of a Dominant-Negative Mutant in Human Cells , 2001, Molecular and Cellular Biology.

[26]  S. Korsmeyer,et al.  The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. , 2000, Molecular cell.

[27]  M. McMahon,et al.  Oncogenic transformation of cells by a conditionally active form of the protein kinase Akt/PKB. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[28]  P. Humphrey,et al.  Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. , 1988, Cancer research.

[29]  K. Kinzler,et al.  Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Waterfield,et al.  Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors. , 2007, Bioorganic & medicinal chemistry.

[31]  M. Waterfield,et al.  Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110alpha inhibitors. , 2007, Bioorganic & medicinal chemistry.

[32]  M. Waterfield,et al.  Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110α inhibitors , 2007 .